[1]邱玉梅.裴氏黄白散治疗易瑞沙所致皮肤不良反应的疗效观察[J].西部中医药,2012,25(11):80-82.
　QIU Yu-mei.Observation on Curative Effects of PeiShi HuangBaiSan in Treating Adverse Reaction of Skin Induced by Gefitinib Tablets[J].Western Journal of Traditional Chinese Medicine,2012,25(11):80-82.
点击复制

裴氏黄白散治疗易瑞沙所致皮肤不良反应的疗效观察
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
25
期数:
2012年11期
页码:
80-82
栏目:
出版日期:
2012-11-15

文章信息/Info

Title:
Observation on Curative Effects of PeiShi HuangBaiSan in Treating Adverse Reaction of Skin Induced by Gefitinib Tablets
文章编号:
1004-6852(2012)11-0080-03
作者:
邱玉梅
甘肃省肿瘤医院，甘肃 兰州 730050
Author(s):
QIU Yu-mei
Gansu Cancer Hospital, Lanzhou 730050, China
关键词:
皮肤不良反应; 裴氏黄白散; 易瑞沙; 治疗; 临床研究性; 护理
Keywords:
adverse reaction of skin;  PeiShi HuangBaiSan;  iressa;  therapy;  clinical study;  nursing
分类号:
R473
文献标志码:
B
摘要:
目的：观察裴氏黄白散外敷治疗易瑞沙所致皮肤不良反应的临床疗效。方法：选取 64 例口服易瑞沙治疗后出现皮肤不良反应的非小细胞肺癌Ⅳ期患者，随机分为观察组和对照组各 32 例。观察组采用裴氏黄白散外敷，对照组采用复方醋酸地塞米松(皮炎平)涂擦，观察 2 组皮肤反应在第 7 天、第 14 天和第 28 天的治疗效果。结果：观察组在第 7 天总有效率为75.0%，对照组为 78.1%，较对照组略低，但无显著性差异(P＞0.05)；观察组第 14 天和第 28 天治疗组总有效率均为 100%，对照组第 14 天和第 28 天总有效率分别为 81.3%、84.4%，观察组明显优于对照组(P＜0.05)。结论：裴氏黄白散外敷治疗分子靶向药物所致皮肤不良反应，具有很好疗效，无明显副作用，不易产生耐药性。
Abstract:
Objective: To approach curative effect of PeiShi HuangBaiSan applied to adverse reaction of skin externally induced by gefitinib tablets. Method: Sixty-four patients of Non-small-cell lung cancer (NSCLC) at stage Ⅳ who took gefitinib tablets and manifested serious adverse reaction were chosen and divided into observation group and control group equally. Observation group used PeiShi HuangBaiSan externally and control group were given with compound dexamethasone acetate cream (PiYanPing) externally. Curative effective of both groups were observed at the 7th, 14th and 28th day. Result: Total effective rate of observation group was 75.0% at the 7th day,lower than 78.1% of control group but without significant difference (P＞ 0.05); total effective rates of observation group were 100% at the 14th and 28th day, obviously superior to 81.3% and 84.4% of control group (P＜ 0.05).Conclusion: PeiShi HuangBaiSan in treating adverse reaction of skin caused by molecule-targeting agents for external use is effective without remarkable side effects.

参考文献/References:

［1］ 孙燕，石远凯.临床肿瘤内科手册［M］.5 版.北京：人民卫生出版社，2007：104-114. ［2］ 沈瑛君.中药药理学［M］.上海：上海科学技术出版社，1997：114-115. ［3］ Lynch TJ Jr，Kim ES，Eaby B，et al.Epidermal growth factor receptor inhibitor-associated cutaneous toxicities：An evolving paradigm in clinical management［J］.The Oncologist，2007，12(5)：610-621. ［4］ Lynch TJ，Bell DW，Sordella R，et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib［J］.N EngL J Med，2004，350 (21)：2129-2139. ［5］ Eberhard DA，Johnson BE，Amler LC，et al.Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib［J］.J Clin Oncol，2005，23(25)：5900-5909. ［6］ 王玉超.《脾胃论》用药特点浅探［J］.甘肃中医，2008，21(6):5-6. ［7］ 孙艳君.中药坐浴治疗肛门疾病 100 例［J］.河北中医，2010，32(8):1146. ［8］ 秦录，佟彦丽，任翠莲.马齿苋合剂治疗湿疹的临床观察［J］.西部中医药，2011，24(9):49-50. ［9］ 魏煊，林瑞芳，王荣幸.聚焦超声联合中药外敷治疗外阴白色病变的临床研究［J］.河北中医，2009，31(7)：1000-1001. ［10］杜敏，黄腾辉.完带汤加味合外治法治疗复发性外阴阴道假丝酵母菌病 68 例［J］.西部中医药，2012，25(4)：78-79. ［11］董晓利.地榆大黄寒冰散治疗带状疱疹 120 例［J］.中国中西医结合外科杂志，2001，7(6)：362.

备注/Memo

备注/Memo:
收稿日期：2012-05-18 作者简介：邱玉梅(1960—)，女，本科，主任护师，甘肃省领军人才第一层次，甘肃省护理学会副理事长兼科研工作委员会主任委员，甘肃省中西医结合学会副理事长兼护理专业委员会主任委员。研究方向：护理管理及肿瘤疾病的中西医结合护理。
更新日期/Last Update: 2012-11-15